Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker QTTB
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | James Silverman | 1.12M | 3.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Opaleye, L.P. | 1.12M | 3.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Opaleye Management Inc. | 1.12M | 3.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Aaron Davis | 2.36M | 7.9% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Boxer Holdings GP, LLC | 2.36M | 7.9% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Boxer Holdings, LP | 2.36M | 7.9% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Boxer Capital Management, LLC | 2.36M | 7.9% | SCHEDULE 13G/A ↗ |
| Oct 28, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Bank of America Corp /DE/ | 2.21M | 7.4% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Fhmls Xii, L.L.C. | 125,039 | 0.4% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Fhmls Xii, L.P. | 125,039 | 0.4% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Frazier Life Sciences XII, L.P. | 125,039 | 0.4% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Fhmls Xi, L.L.C. | 23,029 | 0.1% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Fhmls Xi, L.P. | 23,029 | 0.1% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Frazier Life Sciences XI, L.P. | 23,029 | 0.1% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Fhmlsp, L.L.C. | 1.76M | 5.9% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Fhmlsp, L.P. | 1.76M | 5.9% | SCHEDULE 13G ↗ |
| Oct 9, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Frazier Life Sciences Public Fund, L.P. | 1.76M | 5.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Steven A. Cohen | 1.17M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Point72 Capital Advisors, Inc. | 1.17M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Point72 Asset Management, L.P. | 1.17M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Alex Silverstein | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Sirenia Capital Management LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | James Silverman | 931,000 | 5.5% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Opaleye, L.P. | 931,000 | 5.5% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Opaleye Management Inc. | 931,000 | 5.5% | SCHEDULE 13G/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | QTTB Q32 Bio Inc. | OrbiMed Genesis GP LLC | 625,000 | 2.1% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | QTTB Q32 Bio Inc. | Orbimed Capital GP VII LLC | 3.50M | 11.8% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | QTTB Q32 Bio Inc. | Orbimed Advisors LLC | 4.13M | 13.9% | SCHEDULE 13D/A ↗ |
| Jul 10, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Aaron Davis | 3.15M | 13.3% | SCHEDULE 13G ↗ |
| Jul 10, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Boxer Holdings GP, LLC | 3.15M | 13.3% | SCHEDULE 13G ↗ |
| Jul 10, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Boxer Holdings, LP | 3.15M | 13.3% | SCHEDULE 13G ↗ |
| Jul 10, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Boxer Capital Management, LLC | 3.15M | 13.3% | SCHEDULE 13G ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Abingworth Bioventures VII LP | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Abingworth LLP | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Carlyle Genesis UK LLC | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Carlyle Investment Management L.L.C. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | TC Group, L.L.C. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | CG Subsidiary Holdings L.L.C. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Carlyle Holdings I L.P. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Carlyle Holdings I GP Sub L.L.C. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | Carlyle Holdings I GP Inc. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jul 6, 2026 | SCHEDULE 13G/A (amended) | QTTB Q32 Bio Inc. | The Carlyle Group Inc. | 691,735 | 4.1% | SCHEDULE 13G/A ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | RA Capital Healthcare Fund, L.P. | 2.33M | 9.8% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Rajeev Shah | 2.33M | 9.8% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Peter Kolchinsky | 2.33M | 9.8% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | RA Capital Management, L.P. | 2.33M | 9.8% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | Mark N. Lampert | 2.37M | 10.0% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | BVF Inc/Il | 2.37M | 10.0% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | BVF Partners L P/Il | 2.37M | 10.0% | SCHEDULE 13G ↗ |
| Jun 4, 2026 | SCHEDULE 13G | QTTB Q32 Bio Inc. | BVF GP Holdings LLC | 2.18M | 9.2% | SCHEDULE 13G ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:48 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances